Phase II clinical study of HP-3150 in patients with low back pain.
Phase 2
- Conditions
- ow back pain
- Registration Number
- JPRN-jRCT2080222960
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients in whom low back pain was diagnosed clinically
Exclusion Criteria
-Patients with abnormalities at the planned application site.
-Patients with a serious hematologic disorder, hepatic dysfunction, renal dysfunction, hypertension, heart failure, or another complication that is clinically problematic.
-Patients who have undergone a procedure that may affect assessment of pain, including surgery, nerve block, or percutaneous laser disc decompression, within six months before giving informed consent.
-Patients with pain attributable to a complication whose low back pain cannot be assessed properly.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method